Clinical trials: Gefitinib
Breast Cancer
Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients
The researchers want to learn whether ZD1839 can improve the activity of tamoxifen, a drug that participants will receive for the treatment of the type of breast cancer being studied.
- Trial name
- NCT00206492
- Testing
- Iressa, Tamoxifen
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Baylor Breast Care Center
Non Small Cell Lung Cancer
Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)
This is a phase I study of MK2206 (an AKT inhibitor)and gefitinib in nonsmall cell lung cancer patients who failed prior chemotherapy and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).
- Trial name
- NCT01147211
- Testing
- MK2206
- Where
- Taiwan
- Volunteers
- 21 people
- Sponsor
- National Taiwan University Hospital
Non-small Cell Lung Cancer
Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer
Platinum-based combination chemotherapy, such as gemcitabine-carboplatin, is one of the standard first-line therapy for advanced non-small cell lung cancer (NSCLC).
- Trial name
- ISCAN (NCT01404260)
- Testing
- Gefitinib, Gemcitabine +Carboplatin
- Where
- China
- Volunteers
- 219 people
- Sponsor
- Guangdong Association of Clinical Trials
Acneiform Rash
Evaluating Preventive Therapy With Oint Threolone, Synthomycine or Aqua Cream, for EGFR'I Induced Acneiform Rash
The investigators hypothesized that topical anti-inflammatory treatment could counteract the inflammatory reaction induced by EGFR'Is.
- Trial name
- EGFR'I (NCT01256437)
- Testing
- Threolone ointment, ointment Synthomycine, Aqua cream
- Where
- Israel
- Volunteers
- 90 people
- Sponsor
- Rabin Medical Center
Nonsmall Cell Lung Cancer, EGFR Gene Mutation
EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism
BIM deletion polymorphism might be associated with a poor clinical response to EGFR-TKIs in patients who had NSCLC with EGFR mutations.
- Trial name
- NCT03002844
- Testing
- EGFR-TK Inhibitor, EGFR-TKI, EGFR-TKI and Chemotherapy
- Volunteers
- 50 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Metastatic Breast Cancer
Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer
The purpose of this study is to determine if combination therapy of weekly Taxotere™ with Iressa™ will increase the objective responses in measurable leasions in metastatic breast cancer
- Trial name
- NCT00319618
- Testing
- Gefitinib, Docetaxel
- Where
- Norway
- Volunteers
- 66 people
- Sponsor
- AstraZeneca
Esophageal Cancer
Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gefitinib before surgery may shrink the tumor so that it can be removed.
- Trial name
- NCT00258297
- Testing
- gefitinib, conventional surgery, enzyme inhibitor therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Rochester
Metastatic Pancreatic Carcinoma
Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer
The purpose of this study is to find out what activity the combination of docetaxel and Iressa have against metastatic pancreatic cancer.
- Trial name
- NCT00137761
- Testing
- ZD 1839, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Non-Small Cell Lung Cancer
Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung Cancer
The purpose of this study is to assess the overall response rate to Iressa as a first-line treatment in chemonaive patients with inoperable Non-Small Cell Lung Cancer (NSCLC)
- Trial name
- NCT00173875
- Testing
- Iressa
- Where
- Taiwan
- Volunteers
- 108 people
- Sponsor
- National Taiwan University Hospital
Non-Small-Cell Lung Cancer
Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer
Objective: To compare the efficacy and safety of chemotherapy plus intercalated EGFR-tyrosine kinase inhibitors (TKI) combination therapy with TKI alone therapy as first-line treatment for patients with non-small-cell lung cancer…
- Trial name
- TCL-1 (NCT02031601)
- Testing
- Erlotinib, Gefitinib, Icotinib
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Qilu Hospital of Shandong University
EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
This study is a patient-centered, two-group, three-cohort, multi-center, prospective study to further evaluate the survival benefits and safety of zorifertinib as a first-line treatment in EGFRm+ advanced NSCLC patients with CNS…
- Trial name
- NCT07143045
- Testing
- zorifertinib
- Where
- 34 sites in China
- Volunteers
- 800 people
- Sponsor
- Alpha Biopharma (Jiangsu) Co., Ltd.
Unspecified Childhood Solid Tumor, Protocol Specific
Gefitinib in Treating Children With Refractory Solid Tumors
Phase I trial to study the effectiveness of gefitinib in treating children who have refractory solid tumors. Gefitinib may stop the growth of cancer cells by blocking the enzymes necessary for tumor cell growth
- Trial name
- NCT00040781
- Testing
- gefitinib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of glioblastoma multiforme.
- Trial name
- NCT00016991
- Testing
- gefitinib
- Where
- United States
- Sponsor
- Duke University
Non-small Cell Lung Cancer
Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients
The purpose of this study is to determine whether Icotinib is at least non-inferior to Gefitinib in the treatment of advanced non-small cell lung cancer (NSCLC) patients after one or two chemotherapies.
- Trial name
- ICOGEN (NCT01040780)
- Testing
- Icotinib, Gefitinib
- Where
- 27 sites in China
- Volunteers
- 399 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Colorectal Cancer
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer
Phase I trial to study the effectiveness of ZD 1839 combined with irinotecan, leucovorin, and fluorouracil in treating patients who have locally advanced, locally recurrent, or metastatic colorectal cancer.
- Trial name
- NCT00026364
- Testing
- fluorouracil, gefitinib, irinotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of CNS tumors.
- Trial name
- NCT00025675
- Testing
- gefitinib
- Where
- 12 sites in United States
- Volunteers
- 105 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non Small Cell Lung Cancer
A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer
Lung cancer tumors become resistant to the first generation epidermal growth factor receptor (EGFR) inhibitors erlotinib or gefitinib by changing and increasing the activity of two cell signaling pathways: the cMET pathway and…
- Trial name
- NCT01121575
- Testing
- PF-02341066, PF-00299804
- Where
- 10 sites in United States, Australia
- Volunteers
- 70 people
- Sponsor
- Pfizer
Stage IV Lung Cancer
Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR
Lung Cancer is to become the first cause of death related to cancer in France as it's already the case in United States. At Present, Lung Cancer in women and in men is treated similarly.
- Trial name
- LADIE (NCT01556191)
- Testing
- Gefitinib, Fulvestrant, Erlotinib
- Where
- 61 sites in France
- Volunteers
- 379 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Hepatocellular Carcinoma, Molecular Targeted Therapy
Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma
This is a prospective clinical study aiming to tests the safety and efficacy of lenvatinib in combination with gefitinib in people with lenvatinib resistant hepatocellular carcinoma.
- Trial name
- NCT04642547
- Testing
- Lenvatinib and Gefitinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- RenJi Hospital
Non-small Cell Lung Cancer
Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers
The purpose of this study is to compare the efficacy and safety of chemotherapy followed sequentially by gefitinib versus chemotherapy alone in the first line treatment of non-small cell lung cancer (NSCLC).
- Trial name
- NCT00409006
- Testing
- Pemetrexed, Cisplatin, Gefitinib
- Where
- 7 sites in China, South Korea and 1 more
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company